Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FDA approval for Ferring antifertility Rx

Feb. 6, 1997

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Feb. 6, 1997

Impotence Rx expected to enter phase II this year

Feb. 5, 1997

FDA panel to review Carticel service

Feb. 5, 1997

GelMed receives patent coverage for new use of polymers

Feb. 4, 1997

Novel diabetes treatments reported by Shaman

Feb. 4, 1997

Pfizer claims glycogen phosphorylase inhibitors

Feb. 4, 1997

Successful completion of phase I trial of aerosolized osteoporosis product

Feb. 3, 1997

Inhale/Lilly collaborate on pulmonary delivery of osteoporosis Rx

Feb. 3, 1997

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Feb. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...